Featured Research

from universities, journals, and other organizations

Engineered protein has potential for new anti-inflamatory treatment

Date:
March 11, 2011
Source:
NYU Langone Medical Center / New York University School of Medicine
Summary:
Researchers have created a new protein molecule derived from the growth factor progranulin may provide the basis for new therapies in inflammatory diseases, such as rheumatoid arthritis, according to a new study.

Researchers from across multiple disciplines at NYU Langone Medical Center created a new protein molecule derived from the growth factor progranulin may provide the basis for new therapies in inflammatory diseases, such as rheumatoid arthritis, according to a study published in the March 10, 2011 issue of Science.

"The development of this protein extends our understanding of the molecular mechanisms that drive the growth factors and cytokines control of cartilage development and arthritis," said Chuan-ju Liu, PhD, the lead researcher and associate professor, Departments of Orthopaedic Surgery and Cell Biology, NYU Langone Medical Center. "Whether the protein accounts for all of the anti-inflammatory effects we observed in the study needs to replicated, but we are very encouraged by these initial results."

Over the last 20 years research in rheumatology has focused on identifying cytokines (cell-signaling protein molecules secreted by the glial cells of the nervous system and other cells in the immune system responsible for intercellular communication), leading to the inflammatory and degenerative processes in rheumatoid arthritis. The molecule created and used in this study, called ATSTTRIN (antagonist of TNF/TNFR signaling via targeting to TNF receptors), is a peptide constructed from segments of proteins that originate within a cell, which has a high affinity and specificity for binding to tumor necrosis factor receptors (TNFR).

The researchers suggest that this progranulin-derived protein could result in alternative treatments to those suffering from chronic autoimmune diseases such as rheumatoid arthritis, Crohn's diseases, ulcerative colitis, ankylosing spondylitis, plaque psoriasis and psoriatic arthritis.

Dr. Liu's co-authors include Wei Tang and Yi Lu, Shandong University School of Medicine, Jinan, China and NYU Langone Medical Center; Qing-Yun Tian, Michael L. Dustin and Steven B. Abramson, NYU Langone Medical Center; and Xiu-Ping Yu, Shandong University School of Medicine, Jinan, China.


Story Source:

The above story is based on materials provided by NYU Langone Medical Center / New York University School of Medicine. Note: Materials may be edited for content and length.


Journal Reference:

  1. Wei Tang, Yi Lu, Qing-Yun Tian, Yan Zhang, Feng-Jin Guo, Guang-Yi Liu, Nabeel Muzaffar Syed, Yongjie Lai, Edward Alan Lin, Li Kong, Jeffrey Su, Fangfang Yin, Ai-Hao Ding, Alexandra Zanin-Zhorov, Michael L. Dustin, Jian Tao, Joseph Craft, Zhinan Yin, Jian Q. Feng, Steven B. Abramson, Xiu-Ping Yu and Chuan-Ju Liu. The Growth Factor Progranulin Binds to TNF Receptors and Is Therapeutic Against Inflammatory Arthritis in Mice. Science, 10 March 2011 DOI: 10.1126/science.1199214

Cite This Page:

NYU Langone Medical Center / New York University School of Medicine. "Engineered protein has potential for new anti-inflamatory treatment." ScienceDaily. ScienceDaily, 11 March 2011. <www.sciencedaily.com/releases/2011/03/110310141431.htm>.
NYU Langone Medical Center / New York University School of Medicine. (2011, March 11). Engineered protein has potential for new anti-inflamatory treatment. ScienceDaily. Retrieved July 25, 2014 from www.sciencedaily.com/releases/2011/03/110310141431.htm
NYU Langone Medical Center / New York University School of Medicine. "Engineered protein has potential for new anti-inflamatory treatment." ScienceDaily. www.sciencedaily.com/releases/2011/03/110310141431.htm (accessed July 25, 2014).

Share This




More Health & Medicine News

Friday, July 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com
Condemned Man's US Execution Takes Nearly Two Hours

Condemned Man's US Execution Takes Nearly Two Hours

AFP (July 24, 2014) America's death penalty debate raged Thursday after it took nearly two hours for Arizona to execute a prisoner who lost a Supreme Court battle challenging the experimental lethal drug cocktail. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com
Can Watching TV Make You Feel Like A Failure?

Can Watching TV Make You Feel Like A Failure?

Newsy (July 24, 2014) A study by German researchers claims watching TV while you're stressed out can make you feel guilty and like a failure. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile: iPhone Android Web
          Follow: Facebook Twitter Google+
          Subscribe: RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins